← All trials
NCT04514497
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2021
- Primary completion
- Feb 15, 2023
- Completion date
- Feb 15, 2023
- First posted
- Aug 17, 2020
- Last posted
- Nov 17, 2021
- Enrollment
- 87
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- Yale UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.